| 0.0002 0 (0%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0 |
1-year : | 0 |
| Resists | First : | 0 |
Second : | 0 |
| Pivot price | 0 |
|||
| Supports | First : | 0 |
Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0 |
MA(250) : | 0  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 11.1 |
| RSI | RSI(14): 99.9 |
|||
| 52-week | High : | 0.07 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARDS ] has closed Bollinger Bands are 4900% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Fri, 20 Dec 2024
Aridis Provides Corporate Update - GlobeNewswire
Fri, 20 Dec 2024
Aridis Pharma Secures $6.5M Asset Deal for AR-501, Advances Phase 3 Investment Plans - Stock Titan
Fri, 28 Jun 2024
Aridis Pharmaceuticals CEO buys $50,000 in company stock - Investing.com
Mon, 24 Jun 2024
Aridis Provides Corporate Update - Yahoo Finance
Wed, 12 Jul 2023
Aridis’ AR-301 Monoclonal Antibody is Among the First - GlobeNewswire
Tue, 11 Oct 2022
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 2,000 (K) |
| Shares Short P.Month | 440 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.26 |
| Profit Margin | -5.2 % |
| Operating Margin | -208.4 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.5 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|